Andrew Cunningham
Direttore Tecnico/Scientifico/R&S presso CALCIMEDICA, INC.
Posizioni attive di Andrew Cunningham
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CALCIMEDICA, INC. | Direttore Tecnico/Scientifico/R&S | 23/05/2023 | - |
Storia della carriera di Andrew Cunningham
Precedenti posizioni note di Andrew Cunningham
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Corporate Officer/Principal | 01/02/2021 | 01/04/2022 |
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/07/2018 | 01/02/2021 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01/08/2017 | 01/07/2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 01/12/2012 | 01/06/2014 |
Formazione di Andrew Cunningham
| University College Dublin | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
| Giappone | 2 |
| Regno Unito | 2 |
Posizioni
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 1 |
| Masters Business Admin | 1 |
Settori
| Health Technology | 6 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| CALCIMEDICA, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Aziende private | 2 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Andrew Cunningham
- Esperienza
